Galapagos to Design siRNA-Based Cellular
Assays for Target Validation for Novartis
Galapagos said this week that its Galadeno division has entered into an agreement with Novartis Pharmaceuticals UK to design cellular assays using its SilenceSelect gene knock-down platform.
Galadeno will provide technology, reagents, and support to help Novartis researchers validate drug targets by analyzing protein function in human primary cells. Galadeno will receive payments related to the research services and its SilenceSelect technology.